Levodopa/carbidopa subcutaneous - NeuroDerm

Drug Profile

Levodopa/carbidopa subcutaneous - NeuroDerm

Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroDerm
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 18 Oct 2017 NeuroDerm has been acquired by Mitsubishi Tanabe Pharma Corporation
  • 06 Jun 2017 NeuroDerm announces intention to submit MAA to the EMA for Parkinson's disease by the end of 2018
  • 06 Jun 2017 The EMA accepts the proposed amended protocol for the phase III iNDiGO trial in Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top